|  |  |  |
| --- | --- | --- |
| **Date: June 5, 2025** | | |
| **Topic** | **Discussion/Action** | **Follow-Up** |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a poll link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call.  July meeting will likely be canceled due to the 4th of July holiday unless something important needs to be discussed. | Strawpoll sent with these minutes.  <https://strawpoll.com/poy9keD0QgJ> |
| ClinPGx (CPIC)/PGRN meeting | The [ClinPGx](https://clinpgx.org/?ref=blog.clinpgx.org)/[CPIC](https://cpicpgx.org/?ref=blog.clinpgx.org) 2025 Meeting will be held in collaboration with the [PGRN](https://pgrn.org/?ref=blog.clinpgx.org) in Missoula, Montana, September 10-12, 2025.  Reminders:   1. Abstract: Window closed. Acceptance letters sent last week. If you submitted and haven’t heard a response, please reach out. 2. Meeting registration: <https://www.pgrn.org/event-5921668>    1. **CPIC Member discount code (for members that are not PGRN members):** CPICPGRNMT2025    2. Agenda is posted; speakers to be added.    3. ~12 hours of pharmacist CE will be provided.    4. Hotels are also listed—all about 1 mile away: <https://www.pgrn.org/page-18263> | Register for meeting.  <https://www.pgrn.org/event-5921668>  Book hotel/travel:  <https://www.pgrn.org/page-18263> |
| Guidelines In-Progress | * *TPMT-NUDT15*/thiopurines update – Guideline drafted and being circulated to authors soon. Updating allele function with separate publication from CPIC guideline. * *DPYD*/fluoropyrimidines- Towards the end of evidence review underway with next steps to write recommendations. * *CYP3A5*/Tacrolimus – In evidence review; may have recommendations for *CYP3A4*. * *CYP2D6*/5HT3 Receptor Antagonist – evidence review and guideline drafted. * *CYP2D6*/Antipsychotics – added *CYP3A4* and *CYP2C19*. Evidence review with some recommendations written. * *NAT2*/Hydralazine – Guideline circulated to authors. Allele function manuscript completed for authors to review. * *UGT1A1*/irinotecan- Authorship plan underway. * *HLA:* plan to combine into one big guideline; survey to come to CPIC members about antipsychotic/neurology drugs. Need feedback before proceeding with guideline. * *NAT2*/Isoniazid: plan to update; likely in 2026. | Kelly will continue to update.  To see the guidelines currently being developed go to: <https://cpicpgx.org/prioritization-ofcpic-guidelines/>  Look for HLA survey-coming soon. |
| FDA-Dihydropyrimidine Dehydrogenase Deficiency and the Use of Fluoropyrimidine Chemotherapy Drugs | FDA solicit public comment for information on dihydropyrimidine dehydrogenase (DPD) deficiency and the use of fluorouracil and capecitabine (both fluoropyrimidine chemotherapy drugs).  This is follow-up from an AACR meeting that occurred in January. FDA is interested in the operational and test availability as well as the dose that should be used for partial DPD deficiency.  Link:  <https://www.federalregister.gov/documents/2025/05/20/2025-08960/dihydropyrimidine-dehydrogenase-deficiency-and-the-use-of-fluoropyrimidine-chemotherapy-drugs> | **Due in 15 days.** Utilize link to the left to complete. |
| Comparing commercial pharmacogenetic testing results and recommendations  for antidepressants with established CPIC guidelines | Emili Leary, PharmD  Publication link: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11626124/> | Slides to be posted to CPIC website. |